Treatment-emergent adverse events after infusion of adherent stem cells: the MiSOT-I score for solid organ transplantation

URN to cite this document:: urn:nbn:de:bvb:355-epub-279511
DOI to cite this document:: 10.5283/epub.27951

Dillmann, Johannes ; Popp, Felix C. ; Fillenberg, Barbara ; Zeman, Florian ; Eggenhofer, Elke ; Farkas, Stefan ; Scherer, Marcus N. ; Koller, Michael ; Geissler, Edward K. ; Deans, Robert ; Ladenheim, Deborah ; Loss, Martin ; Schlitt, Hans-Jürgen ; Dahlke, Marc H.

Preview

License: Creative Commons: Attribution 3.0
PDF - Published Version
(552kB)

Date of publication of this fulltext: 20 Mar 2013 12:50

Alternative links to fulltext:Pubmed DOI

Details

Preview

Export bibliographical data

Abstract

BACKGROUND: Cellular therapy after organ transplantation is emerging as an intriguing strategy to achieve dose reduction of classical immunosuppressive pharmacotherapy. Here, we introduce a new scoring system to assess treatment-emergent adverse events (TEAEs) of adherent stem cell therapies in the clinical setting of allogeneic liver transplantation (for example, the MiSOT-I trial Eudract CT: ...